Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically conﬁrmed colorectal or breast cancer receiving capecitabine monotherapy or combination chemotherapy.~* Eligible patients were within 18-70 years of age.~* ECOG score was 0-2.~* Left ventricular ejection fraction (LVEF) \> 50%.~* There was no serious persistent toxicity to capecitabine treatment before screening (laboratory tests ≤ grade 1 (NCI CTCAE 5.0 standard)~* Hand-foot syndrome ≤ grade 2 after recovery from the previous treatment period).~Exclusion Criteria:~* Patients were known allergy to fluorouracil or 5-fluorouracil.~* Patients with complete lack of known dihydropyrimidine dehydrogenase (DPD) activity.~* Patients with abnormal hepatic and renal function (serum creatinine≤ 1.5 ×ULN; CLcr ≥ 51 mL/min; bilirubin≤ 1.5 ×ULN; AST, ALT≤2.5×ULN)~* Needed to accept phenytoin, warfarin, other coumarin derivatives anticoagulants, folic acid, and CYP2C9 substrates during the research.~* Patients with brain metastases or other metastases of the central nervous system (except those who were treated at least 6 months prior to the start of the study and were stable and asymptomatic).

- Gender: ALL
- Minimum Age: 28 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- capecitabine reference formulation at a single dose of 150 mg (Type: ACTIVE_COMPARATOR): 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
- capecitabine test formulation at a single dose of 150 mg (Type: EXPERIMENTAL): The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).